Latest News

Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19

Aug

16

2021

Senhwa Signs Agreement with Taiwan’s CDE for COVID-19 Program Guiding Development of Silmitasertib

Aug

11

2021

Senhwa Announces IND Submission to India's CDSCO of a Phase II Clinical Study for Silmitasertib as a Potential COVID-19 Treatment

Jun

23

2021

Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference

Sep

27

2021

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial of Silmitasertib as a Treatment for Patients with Severe COVID-19.

Jan

22

2021

Senhwa Biosciences Presents Positive Cholangiocarcinoma Data.

Jan

15

2021

Senhwa Biosciences Receives US FDA ‘Study May Proceed’ Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461

Dec

24

2020

Senhwa Biosciences’s Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium

Dec

14

2020